Interferon Beta 1a in Hospitalized COVID-19 Patients
Status:
Enrolling by invitation
Trial end date:
2020-04-24
Target enrollment:
Participant gender:
Summary
The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the
approval of the ethics committee will be conducted on patients who have a positive test
confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be
randomly assigned to the two arms of the study and after completing the course of treatment
and collecting and analyzing the necessary information from each patient, the results of the
study will be published both on this site and in the form of an article in a reputable
international journal.